Full-Time

Associate Director Global Medical Affairs and Health Economics and Outcomes Research

Strategic Sourcing

Updated on 9/3/2026

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$150k - $224.3k/yr

+ Incentive opportunity

Princeton, NJ, USA

In Person

Bachelor's, Master's

Category
Operations & Logistics (1)
Required Skills
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • Experience within the pharmaceutical or biotechnology research and development category, with demonstrated expertise in the discipline.
  • Experience executing research and development sourcing projects that yield preferred or strategic partnerships.
  • Experience interacting with senior-level stakeholders and suppliers.
  • Proficiency in evaluating and developing procurement strategies aligned with research and development stakeholders to maximize efficiency and minimize cost with minimal oversight.
  • Proficiency in negotiating supplier contracts and rate cards to achieve value for money and quality for the organization.
  • Demonstrated proficiency in launching and managing financial key performance indicators for sourcing.
  • Demonstrated proficiency in building successful stakeholder relationships.
  • Expertise in data analysis and extracting actionable observations.
  • A basic understanding of International Council for Harmonisation E6 guidelines and Good Laboratory Practices.
  • Seven to ten years of experience in research and development strategic sourcing roles, including the ability to work through transformational efforts within the team.
  • Executive presence and the ability to tell a story and influence organizational direction at the most senior levels.
  • The ability to anticipate trends, understand implications, and create actionable plans for future needs.
  • Familiarity with emerging procurement technologies.
  • The ability to communicate sourcing concepts clearly and simplify complex technical aspects for business decision-making.
  • A strong customer service focus.
  • Experience listening to client needs and partnering to deliver mutually beneficial results.
  • Specific experience leading large, complex sourcing events in the research and development category.
  • Effective internal and external influencing and negotiating skills across organizational levels.
  • A high degree of analytical skill and the ability to synthesize disparate data into meaningful information for critical business decisions.
  • A strong understanding of the pharmaceutical industry and new-drug development.
  • A Bachelor's degree in Business, Supply Chain, Sciences, or relevant technical expertise.
Responsibilities
  • Build relationships with research and development business partners to develop and enable sourcing strategies aligned with business needs and financial, operational, risk, quality, regulatory, and assurance-of-supply objectives.
  • Manage and identify key supplier relationships through operational delivery, continuous improvement, innovation, performance and relationship measurement, governance, supplier relationship development, and alignment with business and corporate goals.
  • Champion sourcing by monitoring compliance with sourcing policies and processes through stakeholder communication, training, and reporting exceptions and deviations.
  • Identify and drive continuous improvement opportunities within the process area.
  • Drive ten to fifteen percent annual savings within in-scope spend areas.
  • Lead and execute significant, high-value, high-impact sourcing activities with cross-functional teams by assessing category markets, collecting business requirements, soliciting requests for information, proposals, and quotations, leading contractual and rate-card negotiations, and establishing strategic contractual infrastructure.
  • Ensure compliance with company policies, industry regulations, and ethical standards; assess and mitigate supplier risks while driving quality and adhering to regulatory guidelines.
  • Execute the common Strategic Sourcing vision and strategy, partnering with business leaders and key stakeholders to gain perspectives and endorsement.
  • Produce success measurements and processes to capture, consolidate, and report sourcing performance and outcomes against objectives.
  • Provide regular reporting and tracking of sourcing initiatives, including progress, issues, risks, and other important observations, to executive leadership, business leaders, and stakeholders.
  • Provide category expertise regarding changes in the category supplier landscape, including new and existing suppliers.
  • Provide organizational training on the importance of following sourcing policies and processes.
  • Ensure controls meet regulatory requirements, including J-SOX and Third-Party Risk Management.
  • Ensure sourcing best practices, including accurate spend analysis, use of request-for-information, proposal, and quotation tools and templates, contract management, preferred supplier programs, and realization of sourcing savings in financials.
  • Oversee key service-provider relationships by participating in governance and business-review meetings.
  • Lead negotiations for Master Services Agreements, amendments, task orders, and change orders to ensure timely contract execution and budget alignment.
  • Enable the success of the managed service provider model by establishing research and development ways of working, category-specific contract templates, and escalation pathways.
  • Perform daily sourcing-project activities, including developing request-for-information, proposal, and quotation strategies and conducting ongoing contract negotiations.
  • Develop operational metrics for continuous monitoring and process improvement across sourcing projects and report them to sourcing leadership.
  • Ensure assigned sourcing projects have clear objectives, including financial and operational benefits aligned with business stakeholders.
  • Partner with business owners, financial operations, and other process owners to ensure project timelines are met.
  • Actively develop sourcing and financial capabilities.
  • Perform other assigned activities or projects.
Desired Qualifications
  • An advanced degree, such as a Master of Business Administration or Master of Science, is preferred.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.